SGIOY Shionogi (ADR)
- 11.650
- -0.490-4.04%
Shionogi (ADR) News
FunPep - 1Q concludes an option agreement with Shionogi Pharmaceutical regarding the antibody-inducing peptide “FPP004X”
FunPep ＜4881＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 13th. Sales increased 54.8% from the same period last year to 50 billion yen, operating loss was 183 million yen (loss of 378 million yen in the same period last year), ordinary loss was 170 million yen (loss of 343 million yen), and quarterly net loss attributable to parent company shareholders was 168 million yen (341 million yen). About the antibody-inducing peptide project, the antibody-inducing peptide “FPP003” (label
The mood intensifies before the US inflation index is announced
The Nikkei Average rebounded. The transaction closed at 38356.06 yen (estimated turnover of 2.11 billion shares), which rose by 176.60 yen. Overseas media reported that US Intel “will receive funding from a US investment company” in the construction plan for a semiconductor factory in Ireland, and since it was bought in the US market the day before, one part of semiconductor-related stocks etc. became strong in the Tokyo market, and the Nikkei Average rose to 38477.68 yen right after falling close. However, domestic long-term interest rates rose due to speculations about policy normalization by the Bank of Japan
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average rebounded slightly, and Advantest boosted by about 33 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 14 days ago was 102 stocks with price increases, 123 stocks with price drops, and 0 stocks unchanged. The Nikkei Average rebounded slightly. The front-end transaction was closed at 38199.10 yen (estimated turnover of 990 million shares), 19.64 yen higher (+0.05%) compared to the previous day. The US stock market on the 13th was mixed. The Dow average depreciated by $81.33 (-0.21%) to $39431.51, and the Nasdaq rose 47.37 points (+ 0.29%) to 16388
Express News | Shionogi: Covid Treatment Did Not Meet Primary Endpoint of a Statistically Significant Reduction in Time to Sustained Resolution of 15 Common Covid-19 Related Symptoms
Express News | Shionogi: Covid Treatment Ensitrelvir Did Not Meet Primary Endpoint in Global Phase 3 Study
Shionogi: 2023 financial results briefing materials
Shionogi 4Q R&D Expenses Y30.0B Vs. Y27.6B Year Earlier
Shionogi 4Q R&D Expenses Y30.0B Vs. Y27.6B Year Earlier
Shionogi Expects FY HIV Franchise Royalty Income at Y224.6B Vs. Y195.8B
Shionogi Expects FY HIV Franchise Royalty Income at Y224.6B Vs. Y195.8B
Shionogi Expects FY Japan Prescription Drugs Revenue to Fall 11% to Y134.9B
Shionogi Expects FY Japan Prescription Drugs Revenue to Fall 11% to Y134.9B
Shionogi 4Q Net Profit Missed Y37.6B Expected in Poll of Analysts by Visible Alpha
Shionogi 4Q Net Profit Missed Y37.6B Expected in Poll of Analysts by Visible Alpha
Shionogi 4Q Rev Y98.3B Vs. Y88.3B >4507.TO
Shionogi 4Q Rev Y98.3B Vs. Y88.3B >4507.TO
Shionogi & Co FY Net Y162.03B Vs Net Y184.97B
Shionogi & Co. Ltd. (4507.TO) Osaka Year Ended March 31 GROUP 2024 2023 Revenue Y435.08 bln Y426.68 bln Operating Profit Y153.31 bln Y14
Shionogi: Financial Results for the Fiscal Year Ending March 31, 2024 [IFRS] (Consolidated)
Shionogi: Financial results for the fiscal year ending 2024/3〈Supplementary Material〉
The Nikkei Average continued to rise slightly, and the lower limit of the cloud hit the 38200 yen level even with push purchases
The Nikkei Average continued to rise slightly. The front-end transaction was closed at 38243.59 yen (estimated turnover of 1.01 billion shares), which was 14.48 yen higher (+0.04%) compared to the previous business day. The US stock market was mixed on the 10th. The Dow average closed at 39512.84 dollars which was 125.08 dollars higher (+ 0.32%), the NASDAQ was 5.39 points lower (-0.03%) at 16340.87, and the S&P 500 closed at 5222.68, which was 8.60 points higher (+ 0.16%). Soft randy
Taiseiken, Obayashi Corporation, Toray, Shiono Yoshi (13th) (1417-5070)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/13 (Mon) ＜1417＞Miraite One ＜1435＞Robohome＜146A＞Colombia ＜1515＞Nippon Steel Mining ＜1518＞Mitsui Matsushima HD ＜1663＞K&O Energy＜167A＞Ryosan Ryoyo ＜1736＞Autech ＜174
Express News | Shionogi & Co Ltd- Shionogi Will Pay an Upfront Fee of $150 Mln, and Maze Will Be Eligible for Milestone Payments Based on Development, Regulatory and Commercial Achievements Plus Tiered Royalties Based Upon Future Net Sales
Express News | Shionogi & Co Ltd- Exclusive Worldwide License Agreement for Mze001, a Novel Therapeutic Candidate for Treatment of Pompe Disease
Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions
Veritas In Silico---1q recorded research support income etc. in the mRNA-targeted small molecule drug discovery business
Veritas In Silico ＜130A＞ announced financial results for the 1st quarter (24/1/03) of the fiscal year ending 2024/12 on the 7th. Business revenue was 0.32 million yen, operating loss was 65 million yen, ordinary loss was 87 million yen, and quarterly net loss was 87 million yen. Since quarterly financial statements have not been prepared for the first quarter of the fiscal year ending 2024/12, the rate of increase or decrease for the first quarter of the fiscal year ending 2024/12 compared to the same quarter of the previous year is not described. Business revenue for the first quarter was mR
Analysis
Price Target
No Data
